A few days after returning from the ECTRIMS Congress in Copenhagen, Dr Jiwon Oh shares how trial results may affect her day-to-day work in the clinic, particularly in relapsing multiple sclerosis (MS). One highlight that could directly affect patient care was the trial results for tolebrutinib. Although phase 3 trials did not meet their primary endpoint in relapsing-remitting MS, the treatment showed a reduction in disability worsening for nonrelapsing secondary progressive MS as a secondary endpoint.
Dr Oh reveals that she discussed these findings with about 30% of her patients, giving them hope for new treatment options. She also notes reassuring results from longer-term trials of fenebrutinib, another BTK inhibitor, in patients with relapsing MS. In all, as these therapies progress through trials, Dr Oh is hopeful for more treatment options in the near future.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ECTRIMS 2024: The Impact of New Trial Data on Clinical Care - Medscape - Oct 11, 2024.
Comments